Bonaventura Clotet
Bonaventura Clotet
Director irsiCaixa AIDS Research Institute
Verified email at irsicaixa.es
TitleCited byYear
Combination antiretroviral therapy and the risk of myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
18052003
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
Y Cao, L Qin, L Zhang, J Safrit, DD Ho
New England Journal of Medicine 332 (4), 201-208, 1995
13001995
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
R Weber, CA Sabin, N Friis-Moller, P Reiss, WM El-Sadr, O Kirk, F Dabis, ...
Arch Intern Med 166 (15), 1632-41, 2006
12132006
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
1100*2011
Raltegravir with optimized background therapy for resistant HIV-1 infection
RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ...
New England Journal of Medicine 359 (4), 339-354, 2008
7952008
Maraviroc for previously treated patients with R5 HIV-1 infection
RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ...
New England Journal of Medicine 359 (14), 1429-1441, 2008
7802008
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA Panel
MS Hirsch, F Brun-Vézinet, TD Richard, SM Hammer, VA Johnson, ...
Jama 283 (18), 2417-2426, 2000
7692000
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin, B Clotet, D Cooper, J Reynes, K Arastéh, M Nelson, ...
New England Journal of Medicine 348 (22), 2186-2195, 2003
7562003
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management
MS Hirsch, B Conway, TD Richard, VA Johnson, F Brun-Vézinet, B Clotet, ...
Jama 279 (24), 1984-1991, 1998
7121998
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
MS Hirsch, F Brun-Vézinet, B Clotet, B Conway, DR Kuritzkes, ...
Clinical Infectious Diseases 37 (1), 113-128, 2003
6232003
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
A Lazzarin, T Campbell, B Clotet, M Johnson, C Katlama, A Moll, ...
The Lancet 370 (9581), 39-48, 2007
5602007
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ...
New England Journal of Medicine 359 (4), 355-365, 2008
5572008
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two …
B Clotet, N Bellos, JM Molina, D Cooper, JC Goffard, A Lazzarin, ...
The Lancet 369 (9568), 1169-1178, 2007
5522007
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ...
Clinical Infectious Diseases 47 (2), 266-285, 2008
5392008
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460, 2010
4982010
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy
AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ...
Jama 316 (2), 171-181, 2016
4052016
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial
C Tural, L Ruiz, C Holtzer, J Schapiro, P Viciana, J González, P Domingo, ...
Aids 16 (2), 209-218, 2002
4052002
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 …
CB Hicks, P Cahn, DA Cooper, SL Walmsley, C Katlama, B Clotet, ...
The Lancet 368 (9534), 466-475, 2006
3702006
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3 …
CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie, MA Johnson, ...
The Lancet 378 (9787), 229-237, 2011
3472011
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
MR Nelson, C Katlama, JS Montaner, DA Cooper, B Gazzard, B Clotet, ...
Aids 21 (10), 1273-1281, 2007
3432007
The system can't perform the operation now. Try again later.
Articles 1–20